Indeed, pre-clinical studies have suggested that BRAF inhibition in CRC leads to the robust adaptive feedback of signaling networks, including the activation of EGFR, leading to the reactivation of MAPK signaling and sustaining tumor growth [25,26]. The gene discussed is EGFR; the disease is colorectal carcinoma.